Organization will receive The Artist in Residence Program to help people affected by cancer

CHAPEL HILL, NC – Four staff members were honored by UNC Lineberger Comprehensive Cancer Center with the 2010 Oncology Nursing Excellence Awards and the Clinical Services Excellence Awards. Ann Fletcher, Sam Sharf and Liz Sherwood each received a 2010 Oncology Nursing Excellence Award. Dan Roscicki was recognized with a Clinical Services Excellence Award. Dr. Richard … Read more

CHAPEL HILL, NC – The article “Calorie counting is not as easy as you think” written by Rose Pastore and published November 9, 2010 on MarketWatch, part of The Wall Street Digital network, quotes UNC Lineberger member Marci Campbell, PhD, MPH, RD. In the article, she talked about nutrition decisions and what factors impact these … Read more

CHAPEL HILL, NC – A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular “cargo” of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing. In this way, virus-infected … Read more

The article “U.S. Says Genes Should Not Be Eligible for Patents” written by Andrew Pollack and published in the October 29, 2010 issue of The New York Times quotes UNC Lineberger member Jim Evans, MD, PhD. He spoke about the federal government’s recent ruling regarding gene patenting. Dr. Evans is the director of clinical cancer … Read more

G-Zero Therapeutics funded under Qualifying Therapeutic Discovery Project

In a study published this month in the Journal of Clinical Oncology, the results of a clinical trial of the drug bevacizumab to treat colon cancer in combination with the standard therapy found that the drug did not significantly increase disease-free survival in patients with stage II and stage III colon cancer.

Cell signaling protein may hold key to blocking long-studied genetic mutation

Matthew Redinbo, PhD, senior author of a study that relates to the drug CPT-11, or Irinotecan, was motivated to tackle the problem of curbing CPT-11’s side effects after seeing the treatment’s debilitating impact on a colleague, Lisa Benkowski, who contracted colon cancer and subsequently died in 2003. For a long time, he did not share … Read more

CHAPEL HILL, NC – A debilitating side effect of a widely used but harshly potent treatment for colon cancer could be eliminated if a promising new laboratory discovery bears fruit. The pre-clinical finding, published in the Nov. 5, 2010, issue of the journal Science, relates to the drug CPT-11, or Irinotecan, a chemotherapeutic agent used … Read more